OPK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 40 cases where OPK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OPK's RSI Oscillator exited the oversold zone, 22 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on OPK as a result. In 74 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for OPK just turned positive on October 19, 2026. Looking at past instances where OPK's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
OPK moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPK advanced for three days, in 160 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 95 of 141 cases where OPK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for OPK crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.027) is normal, around the industry mean (66.046). P/E Ratio (-23.286) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.134) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. OPK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
UTMD saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 101 similar instances where the indicator turned positive. In 60 of the 101 cases, the stock moved higher in the following days. The odds of a move higher are at 59%.
Following a +0.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTMD advanced for three days, in 144 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
The 10-day RSI Indicator for UTMD moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 11 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 53 cases where UTMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.
The Moving Average Convergence Divergence Histogram (MACD) for UTMD turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 30 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. UTMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.952) is normal, around the industry mean (4.961). P/E Ratio (22.884) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (5.980) is also within normal values, averaging (4.143). Dividend Yield (0.017) settles around the average of (0.005) among similar stocks. P/S Ratio (6.549) is also within normal values, averaging (56.876).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UTMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
OPK | UTMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 85 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 75 | |
PRICE GROWTH RATING 1..100 | 40 | 42 | |
P/E GROWTH RATING 1..100 | 81 | 13 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OPK's Valuation (31) in the Biotechnology industry is somewhat better than the same rating for UTMD (85) in the Medical Specialties industry. This means that OPK’s stock grew somewhat faster than UTMD’s over the last 12 months.
OPK's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as UTMD (100) in the Medical Specialties industry. This means that OPK’s stock grew similarly to UTMD’s over the last 12 months.
UTMD's SMR Rating (75) in the Medical Specialties industry is in the same range as OPK (92) in the Biotechnology industry. This means that UTMD’s stock grew similarly to OPK’s over the last 12 months.
OPK's Price Growth Rating (40) in the Biotechnology industry is in the same range as UTMD (42) in the Medical Specialties industry. This means that OPK’s stock grew similarly to UTMD’s over the last 12 months.
UTMD's P/E Growth Rating (13) in the Medical Specialties industry is significantly better than the same rating for OPK (81) in the Biotechnology industry. This means that UTMD’s stock grew significantly faster than OPK’s over the last 12 months.
| OPK | UTMD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 76% | 1 day ago 52% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 58% |
| Momentum ODDS (%) | 1 day ago 80% | 1 day ago 59% |
| MACD ODDS (%) | 1 day ago 80% | 1 day ago 60% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 46% |
| Advances ODDS (%) | 3 days ago 74% | 3 days ago 58% |
| Declines ODDS (%) | 15 days ago 80% | 18 days ago 51% |
| BollingerBands ODDS (%) | 1 day ago 90% | N/A |
| Aroon ODDS (%) | 1 day ago 67% | N/A |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
OPK’s FA Score shows that 1 FA rating(s) are green while UTMD’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
OPK’s TA Score shows that 8 TA indicator(s) are bullish while UTMD’s TA Score has 2 bullish TA indicator(s).
OPK (@Medical Specialties) experienced а +16.79% price change this week, while UTMD (@Pharmaceuticals: Other) price change was -0.09% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.
OPK is expected to report earnings on Nov 04, 2026.
UTMD is expected to report earnings on Oct 22, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+0.74% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
A.I.dvisor indicates that over the last year, OPK has been loosely correlated with ICUI. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if OPK jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To OPK | 1D Price Change % | ||
|---|---|---|---|---|
| OPK | 100% | +1.87% | ||
| ICUI - OPK | 41% Loosely correlated | +4.66% | ||
| CLPT - OPK | 39% Loosely correlated | N/A | ||
| CRL - OPK | 36% Loosely correlated | -1.51% | ||
| IQV - OPK | 36% Loosely correlated | +0.61% | ||
| UTMD - OPK | 36% Loosely correlated | +0.46% | ||
More | ||||
A.I.dvisor indicates that over the last year, UTMD has been loosely correlated with CERS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if UTMD jumps, then CERS could also see price increases.
| Ticker / NAME | Correlation To UTMD | 1D Price Change % | ||
|---|---|---|---|---|
| UTMD | 100% | +0.46% | ||
| CERS - UTMD | 50% Loosely correlated | -3.35% | ||
| TMCI - UTMD | 47% Loosely correlated | +3.38% | ||
| INMD - UTMD | 47% Loosely correlated | +0.14% | ||
| ITGR - UTMD | 44% Loosely correlated | -0.11% | ||
| IART - UTMD | 43% Loosely correlated | +4.10% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FVD | 50.63 | 1.08 | +2.18% |
| First Trust Value Line Dividend Index Fund (FVD) | |||
| LABD | 7.62 | 0.16 | +2.14% |
| Direxion Daily S&P Biotech Bear 3X ETF (LABD) | |||
| FSMB | 19.69 | 0.07 | +0.36% |
| First Trust Short Duration Managed Municipal ETF (FSMB) | |||
| UJUN | 39.20 | -0.28 | -0.71% |
| Innovator U.S. Equity Ultra Buffer ETF - June (UJUN) | |||
| UGLD | 18.40 | -1.04 | -5.37% |
| Direxion Daily Gold Bull 2X ETF (UGLD) | |||